Vendica Medical, NYC-based urology therapeutics company, raised $11M in funding.
The round was led by Israel Biotech Fund (IBF), alongside key strategic partners, Merz and Laborie.
The company intends to use the funds to accelerate its upcoming Phase 2 clinical trials across the United States and Europe for its treatment of overactive bladder (OAB) using botulinum toxin A (Xeomin®) delivered through a proprietary, needle-free device.
Led by CEO Avner Geva and CTO Avi Eftel, Vensica Medical is a biotechnology company focused on developing novel therapies for urological conditions. Its needle-free delivery system for Xeomin® (botulinum toxin A) is aimed at treating overactive bladder in a minimally invasive manner.
As part of its strategic partnership with Merz, the company has secured exclusive rights to Xeomin® in needle-less therapeutic application in several urologic indications and will benefit from Merz’s clinical development support.
Vensica was established in the incubator program of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), and The Israel Innovation Authority. The company has an office in Herzliya, Israel
FinSMEs
28/10/2024